A director of Precigen Inc. purchased $24,661 worth of the company’s shares on August 21, 2026, according to a regulatory filing.
Nancy H. Agee acquired 3,411 ordinary shares at $7.23 per share, bringing her total direct holdings to 309,187 shares. The transaction was reported on Form 4, the standard disclosure for insider trades.
The purchase follows Precigen’s second-quarter results, which showed revenue of $54.98 million and net income of $20.1 million. Earnings per share reached $0.05, exceeding analyst expectations of a $0.01 loss. Revenue nearly doubled the projected $27.83 million, driven by demand for PAPZIMEOS, the company’s approved therapy for recurrent respiratory papillomatosis in adults.
Precigen’s stock has gained 71% over the past year, trading near its 52-week high of $7.55. Analyst price targets range from $11 to $18, with some valuations indicating the shares are fairly priced at current levels.
